Study on the Efficacy and Safety of Avatricopal in Patients With CLD Complicated With Thrombocytopenia

Inclusion Criteria: * Voluntarily join the study and sign the informed consent; * Age ≥18 years old, male or female; * Baseline platelet count \< 50×10\^9/L; * Patients with chronic liver disease undergoing elective invasive and minimally invasive surgery; * No fertility requirements. Exclusion Criteria: * History of arterial or venous thrombosis within 6 months prior to baseline; * Plan to receive platelet transfusion or platelet-containing blood products within 7 days prior to baseline visit; * Anticoagulant or antiplatelet therapy cannot be suspended before surgery according to the standard (low-dose aspirin is allowed to continue); * currently receiving treatment with recombinant human thrombopoietin or thrombopoietin receptor agonists (such as rhTPO, Etopopal, or romipristine); * The subjects had severe arteriosclerosis, cerebral thrombosis tendency, coronary artery stenosis \> 70%; * Patients with a history of arterial or venous thrombosis within 6 months before enrollment; * Patients with known portal vein blood flow velocity \< 10 cm/s or previous portal vein thrombosis within 6 months before enrollment; * Prior to enrollment, any known primary blood history (e.g., immune thrombocytopenia, myelodysplastic syndrome, aplastic anemia); * A known history of hereditary prethrombotic syndrome prior to admission (e.g., VLeiden mutation, prothrombin G20210A mutation, or hereditary antithrombin III (ATIII) deficiency); * A history of major cardiovascular disease within the 6 months prior to enrollment (e.g., aggravated congestive heart failure, arrhythmias known to increase the risk of thromboembolic events \[such as atrial fibrillation\], coronary or peripheral arterial stenting or angioplasty, and coronary or peripheral arterial bypass grafting); * the subject is allergic to avatripopal or any of its excipients; * Exclude vulnerable people with mental disorders and other disabilities * The investigator believes that accompanying medical history may affect the safe completion of the study.